In a small-scale prospective, single-center, randomized double-blinded trial, Gao et al. found XBJ significantly lowered IL-1β, IL-8, and C-reactive protein in blood and up-regulated IL-10 in blood and decreased adverse events in patients with lung injury (Gao et al., 2018). The gene discussed is IL10; the disease is injury.